Padernal, Michelle .
HRN: 27-13-68 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/21/2025
CO-AMOXICLAV 625MG (TAB)
05/21/2025
05/28/2025
ORAL
625mg
BID
S/P NSD; PROM
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes